FOLD is now overvalued and could go down -30%

Based on our analysis, Amicus Therapeutics has received an overvalued rating of 1 out of 5 stars from Cashu, primarily due to several concerning financial metrics. The Price-to-Book (PB) Ratio for Amicus Therapeutics stands at 14.51, significantly higher than the sector average of 2.71. This ratio indicates how much investors are willing to pay for each dollar of net assets. A high PB ratio suggests that the market may be overestimating the company's value relative to its actual net asset value, which can be a red flag for potential investors. In terms of profitability, the company's Net Profit Margin is -10.62, contrasting with the sector's -137.10. While Amicus has a less negative margin than its peers, it still indicates ongoing challenges in turning revenue into profit. This raises questions about the company's efficiency and operational management. Additionally, Amicus’s Return on Equity (ROE) Ratio is -28.91, compared to the sector average of -75.29. Although this reflects a better performance relative to its peers, a negative ROE indicates that shareholders are not currently receiving a return on their investment, which can deter potential investors. Finally, the Return on Assets (ROA) Ratio for Amicus is -7.15, while the sector average is -47.67. Again, while Amicus performs better than the industry average, a negative ROA signals inefficiency in using assets to generate earnings. These metrics suggest that Amicus Therapeutics may be overvalued when considering its financial performance relative to industry standards. This is not a comprehensive overview of our valuation, and should not be viewed as financial advice. Always do your own research before considering an investment.